Is LDL-C a better monitoring choice than triglycerides on survodutide?

Stated plainly: LDL-C · triglycerides · survodutide.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

Is there a defensible reason to prefer one, or is this a coin flip?

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Decide the action for each result before you order the test.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

This is answerable, and the answer is mostly about which tests rather than how many.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

edited 10 Aug 2026 by Dr_Hanne_Solberg — updated for the 2026 guidance change